Uptake of pharmaceuticals within cyclodextrin-based porous materials

A pharmaceutical complex comprising:

• an offset channel metal organic framework comprising γ-cyclodextrin tori linked to one another through the alkali metal cations to form channels that are stacked in an offset manner down the crystallographic a-axis of the metal organic framework and has the chemical formula C96H169X3O84.5, 3H2O, where X is an alkali metal element, and crystallizes in the P1 space group;
• and
• deprotonated drug molecules associated with the alkali metal cations as charge-balancing anions.

A method of forming a pharmaceutical complex, the method comprising:

• forming a solution comprising the free-acid form of acidic drug molecules and metal organic frameworks in a water-soluble, polar organic solvent, wherein the metal organic frameworks comprise γ-cyclodextrin tori coordinated to alkali metal cations on primary and secondary faces of the γ-cyclodextrin tori and further comprises charge compensating anions associated with the alkali metal cations, wherein the metal organic framework is an offset channel metal organic framework comprising γ-cyclodextrin tori linked to one another through the alkali metal cations to form channels that are stacked in an offset manner down the crystallographic a-axis of the metal organic framework and has the chemical formula C96H169X3O84.5, 3H2O, where X is an alkali metal element, and crystallizes in the P1 space group, and further wherein the polar organic solvent facilitates the deprotonation of the free-acid form of the acidic drug molecules;
• and
• allowing the deprotonated acidic drug molecules to undergo anion exchange with the charge compensating anions of the metal organic frameworks to form metal organic frameworks loaded with deprotonated acidic drug molecules.

A method of forming a pharmaceutical complex, the method comprising:

• forming a solution comprising an alkali metal salt of a drug molecule, γ-cyclodextrin, and an organic alcohol;
• and
• co-crystallizing the alkali metal salt of the drug molecule and the γ-cyclodextrin in the presence of the organic alcohol to form a metal organic framework comprising γ-cyclodextrin tori coordinated to alkali metal cations on primary and secondary faces of the γ-cyclodextrin tori, wherein the metal organic framework is an offset channel metal organic framework comprising γ-cyclodextrin tori linked to one another through the alkali metal cations to form channels that are stacked in an offset manner down the crystallographic a-axis of the metal organic framework and has the chemical formula C96H169X3O84.5bl , 3H2O, where X is an alkali metal element, and crystallizes in the P1 space group, wherein the drug molecules are associated with the alkali metal cations as charge-balancing anions.